University of Houston Scientists Repurpose Cancer Drugs to Resolve Intestinal Stress in Crohn’s Disease Treatment Breakthrough

University of Houston researchers find that low-dose cancer meds can stop the cell death cycle in Crohn's disease, allowing the intestinal lining to regenerate.

By: AXL Media

Published: Apr 28, 2026, 8:52 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Paradigm Shift in Inflammatory Bowel Disease

Researchers at the University of Houston are challenging the traditional medical approach to Crohn’s disease, which has historically focused on managing the immune system’s overreaction. Instead of treating the symptoms of inflammation, this new study targets the inherent defects in the epithelial lining that trigger the immune response in the first place. According to Seema Khurana, Moores Professor of biology and biochemistry, identifying these drivers brings the medical community closer to a fundamental understanding of what causes the disease rather than just suppressing its flares.

The Destructive Cycle of Cellular Stress

The study reveals that in patients with Crohn’s disease, the cells lining the gut are under a state of permanent "stress signaling" that never switches off. In a healthy body, these signals fluctuate to manage cellular repair, but the constant activation in patients leads to necroptosis, a form of programmed cell death. When these cells die off instead of regenerating, the "gut barrier" is compromised, allowing toxins and bacteria to leak into the body. This leakage fuels the chronic inflammatory cycle that affects approximately 1 million Americans.

Repurposing Oncology Meds for Gut Repair

To break this cycle, the research team discovered that low concentrations of two specific cancer medications, Pazopanib and Ponatinib, can inhibit the stress signals. By dampening the initial cellular response that leads to cell death, these drugs allow the intestinal lining to begin its natural process of repair and regeneration. According to the study published in Gastro Hep Advances, these medications act as a catalyst for the body to heal itself, shifting the focus from anti-inflammatory suppression to active barrier restoration.